Background: Loxapine inhalation powder delivered by a hand-held device as a thermally generated aerosol (ADASUVE) was recently approved in the United States and European Union for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. As smokers comprise a large subpopulation of these patients, and many antipsychotic drugs require dose adjustments for smokers, the objective of this study was to compare the pharmacokinetics of inhaled loxapine administered to smokers and nonsmokers.
Methods: Pharmacokinetics and sedation pharmacodynamics using a visual analog scale were studied in 35 male and female adult subjects (18 nonsmokers and 17 smokers) following a single dose of 10 mg of inhaled loxapine. Blood samples were drawn at predose, 30 seconds, 1, 2, 3, 10, 30, and 60 minutes, and 2, 6, 12, and 24 hours after dosing. Loxapine and 8-OH-loxapine were analyzed using reverse-phase liquid chromatography coupled with a tandem mass spectrometer. Pharmacokinetic parameters assessed included Cmax, Tmax, AUCinf, and T1/2 for loxapine and 8-OH-loxapine. Geometric mean ratios (GMRs) were determined for smokers to nonsmokers.
Results: Loxapine Cmax was similar in smokers and nonsmokers with a GMR of 99.0%. The median loxapine Tmax was 1.88 and 1.01 minutes for nonsmokers and smokers, respectively. Loxapine AUCinf and AUClast values in nonsmokers were comparable with smokers (GMRs of 85.3% and 86.7%, respectively). A slight decrease in the observed mean terminal half-life values was observed for smokers (6.52 hours for smokers and 7.30 hours for nonsmokers).
Conclusions: Sedation profiles and visual analog scale scores at each time point were similar for nonsmokers and smokers. It was concluded that inhaled loxapine does not require dosage adjustment based on smoking behavior.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218760 | PMC |
| http://dx.doi.org/10.1097/FTD.0000000000000048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alternative Approaches for Addressing Acute Agitation in Schizophrenia and Bipolar Disorder.
Prim Care Companion CNS Disord
January 2024
Clinical Development and Medical Affairs, Neurelis, Inc, San Diego, California.
The prompt effective treatment of acute agitation among patients with schizophrenia or bipolar disorder can alleviate distressing symptoms for the patient and decrease the risk of escalation to aggression and the potential for serious harm to the patient, health care providers, and others. A commonly used approach for the management of acute agitation has been the intramuscular administration of antipsychotic medications and/or benzodiazepines. However, US Food and Drug Administration-approved treatments with alternative routes of delivery now include inhaled loxapine powder and, more recently, dexmedetomidine sublingual film.
View Article and Find Full Text PDFEfficacy and Safety of Loxapine in Acute Agitation: A Systematic Review of Interventional Studies.
Prim Care Companion CNS Disord
December 2023
Service de Psychiatrie Adultes, Centre Hospitalier Universitaire, Dijon, France.
Article Synopsis
- A systematic review was conducted to evaluate the effectiveness and safety of loxapine for treating acute agitation, using several medical databases to gather relevant studies published until March 2022.
- From 1,435 articles screened, 7 studies with 1,276 participants were selected, revealing that loxapine was more effective and quicker than other treatments like placebo and haloperidol.
- Despite some methodological limitations, the findings suggest that loxapine is generally well-tolerated with only mild to moderate side effects, indicating its potential as a reliable option for managing acute agitation.
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder.
Expert Opin Pharmacother
November 2023
Department of Psychiatry and Behavioral Sciences, New York Medical College, New York, Valhalla, USA.
Introduction: Agitation is commonly encountered in people with bipolar disorder, particularly when experiencing a manic episode. The number of approved pharmacological agents to manage acute episodes of agitation in this population is limited.
Areas Covered: A search was conducted using the US National Library of Medicine PubMed.
Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond.
Expert Rev Neurother
August 2022
Department of Psychiatry, University Hospital, Clermont Ferrand, France.
Introduction: Acute behavioral disturbances in psychosis, including agitation, comprise a heterogeneous group of manifestations varying in intensity and duration they last for. They require rapid, non-coercive treatments ranging from verbal de-escalation to the calming effect of pharmacological agents. The treatment goals are reduction of patient suffering and prevention of disease deterioration.
View Article and Find Full Text PDFInhaled Loxapine as a Rapid Treatment for Agitation in Patients with Personality Disorder: A Prospective Study on the Effects of Time.
Clin Psychopharmacol Neurosci
August 2022
Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain.
Objective: Agitation in patients diagnosed with personality disorders (PD) is one of the most frequent crises in emergency departments (ED). Although many medications have been tested, their effectiveness has been small or non-significant, and no specific drugs are supported by the available evidence. This study aimed to evaluate the efficacy of Inhaled loxapine (IL) as a therapeutic option for agitated patients with PD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!